Phaseline

Companies › Entrada Therapeutics

Entrada Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Neurology; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ENTR-601-45
Antisense oligonucleotide for exon 45 skipping in DMD
–Phase 1Duchenne Muscular Dystrophy (DMD)Mar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07038824ENTR-601-45Phase 1Duchenne Muscular Dystrophy (DMD)NeurologyMar 2029
NCT07037862ENTR-601-45Phase 1Duchenne Muscular Dystrophy (DMD)NeurologyMar 2029

From the company's SEC filings

Cash and short-term investments of $193m on 2026-09-30; operating cash outflow about $140m a year; runway about 17 months at that burn, to Feb 2028

Press releases filed as 8-K in the last year:

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.